Zura Bio Ltd (ZURA) Form 8-K — Jun 18, 2026
Zura Bio Limited shareholders approved the Amended and Restated 2023 Equity Incentive Plan during the Annual General Meeting held on June 17, 2026. The plan reserves 9,594,213 Ordinary Shares and includes an evergreen provision to increase the reserve by 5% annually from 2027 through 2029 to facilitate talent retention. Shareholders also ratified the appointment of WithumSmith+Brown, PC as the independent auditor for the fiscal year ending December 31, 2026, and elected eight directors to the Board. The voting results indicated approval for all director nominees and the auditor, with the incentive plan approval receiving 38.8 million votes in favor against 17.4 million votes opposed.
Key figures
- Plan Votes For
- 38850373
- Chair Monthly Pay
- 25000
- Plan Votes Abstain
- 26663
- Plan Votes Against
- 17403607
- Director Comp Limit
- 750000
- Aggregate Share Limit
- 9594213
- Evergreen Percentage
- 5.0%
- Director Comp Limit First Year
- 1000000
Price after filing
Close on the filing date to close N calendar days later (from $3.75). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.